299 results on '"Chatenet†, David"'
Search Results
52. Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord
53. Towards Targeting the Urotensinergic System: Overview and Challenges
54. Targeting the PAC1 Receptor for Neurological and Metabolic Disorders
55. Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides
56. Antibacterial properties of the pituitary adenylate cyclase-activating polypeptide: A new human antimicrobial peptide
57. Synthesis of P-chiral enephosphonic acid derivatives
58. Urotensin core mimics that modulate the biological activity of urotensin-II related peptide but not urotensin-II
59. Discovery of New Allosteric Modulators of the Urotensinergic System through Substitution of the Urotensin II-Related Peptide (URP) Phenylalanine Residue
60. New insights about the peculiar role of the 28–38 C-terminal segment and some selected residues in PACAP for signaling and neuroprotection
61. A New Approach to Inhibit Prototypic Galectins
62. New directions for urotensin II receptor ligands
63. Design, Synthesis, and Biological Assessment of Biased Allosteric Modulation of the Urotensin II Receptor Using Achiral 1,3,4-Benzotriazepin-2-one Turn Mimics
64. Design of peptidic inhibitors targeting the dimerization interface of galectins
65. How to improve PACAP efficiency for neuroprotection and neurorepair?
66. Intracellular Angiotensin‐II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion
67. Peptide modification results in the formation of a dimer with a 60-fold enhanced antimicrobial activity
68. Design, Synthesis, and Biological Assessment of Biased Allosteric Modulation of the Urotensin II Receptor Using Achiral 1,3,4-Benzotriazepin-2-one Turn Mimics
69. Urotensin II(4–11) Azasulfuryl Peptides: Synthesis and Biological Activity
70. Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in in vitro and in vivo models of Parkinson's disease
71. Caged ligands to study the role of intracellular GPCRs
72. Intracrine endothelin signaling evokes IP3-dependent increases in nucleoplasmic Ca²⁺ in adult cardiac myocytes
73. Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin
74. De Novo Conception of Small Molecule Modulators Based on Endogenous Peptide Ligands: Pyrrolodiazepin-2-one γ-Turn Mimics That Differentially Modulate Urotensin II Receptor-Mediated Vasoconstriction ex Vivo
75. Acute food deprivation reduces expression of diazepam-binding inhibitor, the precursor of the anorexigenic octadecaneuropeptide ODN, in mouse glial cells
76. Synthesis of N-Methyl and Azasulfuryl Urotensin-II(4-11) Derivatives
77. International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function
78. Secondary conformational conversion is involved in glycosaminoglycans-mediated cellular uptake of the cationic cell-penetrating peptide PACAP
79. Identification of an unusual cleavage site for the prolyl endopeptidase: investigation of the breakdown of the octadecaneuropeptide ODN. Peptides 2004, Proceedings of the 3rd International and 28th European Peptide Symposium, pp 890-891
80. Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 2004. Proceedings of the 3rd International and 28th European Symposium, pp 804-805
81. Design of a Truncated Cardiotoxin-I Analogue with Potent Insulinotropic Activity
82. Development and Pharmacological Characterization of Conformationally Constrained Urotensin II-Related Peptide Agonists
83. Structure-activity relationship of human urotensin II. Peptides 2002, Proceedings of the 27th European Peptide Symposium, pp176-177
84. Structure-activity relationship of rat octadecaneuropeptide: importance of the leucine residues. Peptides 2002, Proceedings of the 27th European Peptide Symposium, pp 544-545
85. Design and Application of Light-Activated Probes for Cellular Signaling.
86. Regulation of cardiac nitric oxide signaling by nuclear β-adrenergic and endothelin receptors
87. Update on the urotensinergic system: new trends in receptor localization, activation, and drug design
88. Urotensin II(4-11) Azasulfuryl Peptides: Synthesis and Biological Activity.
89. Cardiotoxin-I: An Unexpectedly Potent Insulinotropic Agent
90. Presence of urotensin-II receptors at the cell nucleus: Specific tissue distribution and hypoxia-induced modulation
91. Regulation of nitric oxide synthesis by beta‐adrenergic receptors in the nuclear envelope
92. Receptor-independent cellular uptake of pituitary adenylate cyclase-activating polypeptide
93. Characterization of iodinated adrenomedullin derivatives suitable for lung nuclear medicine
94. The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation
95. Structure−Activity Relationships of a Novel Series of Urotensin II Analogues: Identification of a Urotensin II Antagonist
96. Structure–Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction
97. Design of a Truncated Cardiotoxin-IAnaloguewith Potent Insulinotropic Activity.
98. Development and PharmacologicalCharacterization ofConformationally Constrained Urotensin II-Related Peptide Agonists.
99. International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function
100. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.